Concepedia

Author

Christine Christian

University of California, San Francisco

Also Known As

C Christian, C. Christian, Camm Christian, Christian C. Abnet (190748), Christine Christian

11

Publications

439

Citations

8

H-Index

26

Concepts

All Affiliations

University of California, San FranciscoUCSF Helen Diller Family Comprehensive Cancer CenterCancer Research Institute
CC

About

Christine Christian is an author at University of California, San Francisco specializing in radiation oncology, tumor biology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

252

2

Cell Biology

2

2

169

3

Immunology

2

2

169

4

Endocrinology

1

1

16

5

Obstetrics

1

1

16

Christine Christian

×

7

Publications

376

Citations

7

H-Index

YearCitations

Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells.

Mario Anders, Christine Christian, Martin McMahon,

PubMed

2003

99

Multiple intracellular signaling pathways of the neuropeptide substance P receptor

Masato Mitsuhashi, Y. Ohashi, Shigeki Shichijo,

Journal of Neuroscience Research

1992

77

Transforming Growth Factor-β Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition

Markus D. Lacher, Maarit Tiirikainen, Elise F. Saunier,

Cancer Research

2006

70

Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation

W. Michael Korn, Mónica Macal, Christine Christian,

Cancer Gene Therapy

2006

67

Stimulation of Transcriptional Regulatory Activity by Substance P

Christine Christian, M. Jean Gilbert, Donald G. Payan

NeuroImmunoModulation

1994

25

RNA interference-mediated knockdown of p21WAF1 enhances anti-tumor cell activity of oncolytic adenoviruses

Marisa Shiina, Markus D. Lacher, Christine Christian,

Cancer Gene Therapy

2009

22

Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy

Pamela N. Münster, M. Lacevic, Scott Thomas,

Journal of Clinical Oncology

2009

16

Page 1